{(1S,2R)-3-[(5-Amino-2,2-dimethyl-pentyl)-(benzo[1,3]dioxole-5-sulfonyl)-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester | 288292-12-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {(1S,2R)-3-[(5-Amino-2,2-dimethyl-pentyl)-(benzo[1,3]dioxole-5-sulfonyl)-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester
• 英文别名: (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl {(1S,2R)-3-[(5-amino-2,2-dimethylpentyl)(1,3-benzodioxol-5-ylsulfonyl)amino]-1-benzyl-2-hydroxypropyl}carbamate；[(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(5-amino-2,2-dimethylpentyl)-(1,3-benzodioxol-5-ylsulfonyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
• CAS: 288292-12-6
• 化学式: C₃₁H₄₃N₃O₉S
• 分子量: 633.763
• InChiKey: VBKYKUHUVHNPMS-KTJDEMTHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  44
• 可旋转键数：
  15
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  167
• 氢给体数：
  3
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  异氰酸甲酯 、 {(1S,2R)-3-[(5-Amino-2,2-dimethyl-pentyl)-(benzo[1,3]dioxole-5-sulfonyl)-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester 以 四氢呋喃 为溶剂， 以77%的产率得到((1S,2R)-3-{(Benzo[1,3]dioxole-5-sulfonyl)-[2,2-dimethyl-5-(3-methyl-ureido)-pentyl]-amino}-1-benzyl-2-hydroxy-propyl)-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester
  参考文献：
  名称：

  Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains

  摘要：

  A novel series of P1' chain-extended arylsufonamides was synthesiszed and evaluated for wild-type HIV protease inhibitory activity and in vitro antiviral activity against wild type virus and two protease inhibitor-resistant mutant viruses. All of the compounds showed dramatic increases in enzyme activity as compared to the currently marketed HIV protease inhibitors amprenavir, indinavir, and nelfinavir. In addition, significant improvements in antiviral potencies against wild type and the two mutant viruses were also realized. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.008
• 作为产物：
  描述：

  (3R,3AS,6AR)-六氢呋喃并[2,3-B]呋喃-3-基(4-硝基苯基)碳酸盐 在 palladium on activated charcoal 、 镍 4-二甲氨基吡啶 、 氨 、 氢气 、 三乙酰氧基硼氢化钠 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 生成 {(1S,2R)-3-[(5-Amino-2,2-dimethyl-pentyl)-(benzo[1,3]dioxole-5-sulfonyl)-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester
  参考文献：
  名称：

  Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains

  摘要：

  A novel series of P1' chain-extended arylsufonamides was synthesiszed and evaluated for wild-type HIV protease inhibitory activity and in vitro antiviral activity against wild type virus and two protease inhibitor-resistant mutant viruses. All of the compounds showed dramatic increases in enzyme activity as compared to the currently marketed HIV protease inhibitors amprenavir, indinavir, and nelfinavir. In addition, significant improvements in antiviral potencies against wild type and the two mutant viruses were also realized. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.008

文献信息

• Inhibitors of aspartyl protease
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20020198388A1

  公开（公告）日：2002-12-26

  The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

  本发明涉及一种新型磺酰胺类物质，其为天冬氨酸蛋白酶抑制剂。在一种实施例中，本发明涉及一种新型的HIV天冬氨酸蛋白酶抑制剂，其具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适合于抑制HIV-1和HIV-2蛋白酶活性，因此可以作为抗HIV-1和HIV-2病毒的抗病毒剂优势使用。本发明还涉及使用本发明化合物抑制HIV天冬氨酸蛋白酶活性的方法以及筛选具有抗HIV活性的化合物的方法。
• INHIBITORS OF ASPARTYL PROTEASE
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1159278B1

  公开（公告）日：2005-11-30
• US6319946B1
  申请人：——

  公开号：US6319946B1

  公开（公告）日：2001-11-20
• US6617350B2
  申请人：——

  公开号：US6617350B2

  公开（公告）日：2003-09-09
• US7442718B2
  申请人：——

  公开号：US7442718B2

  公开（公告）日：2008-10-28